India's Cadila launches first cheaper copy of world's top-selling drug

MUMBAI (Reuters) - Indian drugmaker Cadila Healthcare Ltd said on Tuesday it launched in India the first biosimilar version of the anti-inflammatory medicine adalimumab, the world's top-selling drug, at a fifth of its U.S. price. The drug's branded version is sold under the name Humira by U.S. firm AbbVie Inc, and costs $1,000 for a vial in the United States. Humira had sales of $3.26 billion in the quarter ended September, accounting for 65 percent of AbbVie's total revenue. ...



via Health News Headlines - Yahoo News http://ift.tt/1GdzcP1